铁死亡在常见皮肤病中的研究进展

doi:10.35541/cjd.20220783

Abstract

Abstract: 【Abstract】 Ferroptosis is a new type of iron-dependent cell death, which is mainly caused by the decreased bioactivity of glutathione peroxidase 4, lipid peroxidation, and excessive accumulation of reactive oxygen species. It involves many fine and complex regulatory mechanisms, including iron metabolism, lipid metabolism, amino acid metabolism, and oxidation/antioxidant system. In recent years, studies have shown that ferroptosis is involved in the occurrence and development of some common skin diseases. This review summarizes research progress in the role and mechanisms of action of ferroptosis in common skin diseases, aiming to bring new research directions and ideas for the treatment of skin diseases.

Key words: Cell death, Skin diseases, Ferroptosis, Glutathione peroxidase 4, Vitiligo, Psoriasis, Melanoma, Lupus erythematosus, systemic

Liu Lyuye, Zhang Junling. Ferroptosis in common skin diseases[J]. Chinese Journal of Dermatology,2024,e20220783. doi:10.35541/cjd.20220783

References ［43］

［1］	Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron⁃dependent form of nonapoptotic cell death［J］. Cell, 2012,149（5）:1060⁃1072. doi: 10.1016/j.cell.2012.03.042.
［2］	陈丽华, 向阳. 铁死亡在肿瘤免疫治疗的研究进展［J］. 肿瘤预防与治疗, 2022,35（8）:765⁃769. doi: 10.3969/j.issn.1674⁃0904.2022.08.014.
［3］	Chen X, Comish PB, Tang D, et al. Characteristics and biomarkers of ferroptosis［J］. Front Cell Dev Biol, 2021,9:637162. doi: 10.3389/fcell.2021.637162.
［4］	Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease［J］. Nat Rev Mol Cell Biol, 2021,22（4）:266⁃282. doi: 10.1038/s41580⁃020⁃00324⁃8.
［5］	Nagasaki T, Schuyler AJ, Zhao J, et al. 15LO1 dictates glutathione redox changes in asthmatic airway epithelium to worsen type 2 inflammation［J］. J Clin Invest, 2022,132（1）:e151685. doi: 10.1172/JCI151685.
［6］	Lei G, Zhuang L, Gan B. Targeting ferroptosis as a vulnerability in cancer［J］. Nat Rev Cancer, 2022,22（7）:381⁃396. doi: 10. 1038/s41568⁃022⁃00459⁃0.
［7］	Li J, Cao F, Yin HL, et al. Ferroptosis: past, present and future［J］. Cell Death Dis, 2020,11（2）:88. doi: 10.1038/s41419⁃020⁃2298⁃2.
［8］	Lei G, Zhang Y, Hong T, et al. Ferroptosis as a mechanism to mediate p53 function in tumor radiosensitivity［J］. Oncogene, 2021,40（20）:3533⁃3547. doi: 10.1038/s41388⁃021⁃01790⁃w.
［9］	Chu B, Kon N, Chen D, et al. ALOX12 is required for p53⁃mediated tumour suppression through a distinct ferroptosis pathway［J］. Nat Cell Biol, 2019,21（5）:579⁃591. doi: 10.1038/s41556⁃019⁃0305⁃6.
［10］	Ji H, Wang W, Li X, et al. p53: a double⁃edged sword in tumor ferroptosis［J］. Pharmacol Res, 2022,177:106013. doi: 10.1016/j.phrs.2021.106013.
［11］	Wang Y, Zhao Y, Ye T, et al. Ferroptosis signaling and regulators in atherosclerosis［J］. Front Cell Dev Biol, 2021,9:809457. doi: 10.3389/fcell.2021.809457.
［12］	Dodson M, Castro⁃Portuguez R, Zhang DD. NRF2 plays a critical role in mitigating lipid peroxidation and ferroptosis［J］. Redox Biol, 2019,23:101107. doi: 10.1016/j.redox.2019.101107.
［13］	Zhao Y, Lu J, Mao A, et al. Autophagy inhibition plays a protective role in ferroptosis induced by Alcohol via the p62⁃Keap1⁃Nrf2 pathway［J］. J Agric Food Chem, 2021,69（33）:9671⁃9683. doi: 10.1021/acs.jafc.1c03751.
［14］	Chen J, Li X, Ge C, et al. The multifaceted role of ferroptosis in liver disease［J］. Cell Death Differ, 2022,29（3）:467⁃480. doi: 10.1038/s41418⁃022⁃00941⁃0.
［15］	Doll S, Freitas FP, Shah R, et al. FSP1 is a glutathione⁃independent ferroptosis suppressor［J］. Nature, 2019,575（7784）:693⁃698. doi: 10.1038/s41586⁃019⁃1707⁃0.
［16］	Bersuker K, Hendricks JM, Li Z, et al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis［J］. Nature, 2019,575（7784）:688⁃692. doi: 10.1038/s41586⁃019⁃1705⁃2.
［17］	Wang W, Green M, Choi JE, et al. CD8（+） T cells regulate tumour ferroptosis during cancer immunotherapy［J］. Nature, 2019,569（7755）:270⁃274. doi: 10.1038/s41586⁃019⁃1170⁃y.
［18］	Wu J, Minikes AM, Gao M, et al. Intercellular interaction dictates cancer cell ferroptosis via NF2⁃YAP signalling［J］. Nature, 2019,572（7769）:402⁃406. doi: 10.1038/s41586⁃019⁃1426⁃6.
［19］	Lee H, Zandkarimi F, Zhang Y, et al. Energy⁃stress⁃mediated AMPK activation inhibits ferroptosis［J］. Nat Cell Biol, 2020,22（2）:225⁃234. doi: 10.1038/s41556⁃020⁃0461⁃8.
［20］	李春英, 李舒丽. 白癜风发病机制研究热点解析［J］. 中华皮肤科杂志, 2019,52（9）:593⁃597. doi: 10.3760/cma.j.issn.0412⁃4030.2019.09.001.
［21］	Xuan Y, Yang Y, Xiang L, et al. The role of oxidative stress in the pathogenesis of vitiligo: a culprit for melanocyte death［J］. Oxid Med Cell Longev, 2022,2022:8498472. doi: 10.1155/2022/8498472.
［22］	Villalpando⁃Rodriguez GE, Blankstein AR, Konzelman C, et al. Lysosomal destabilizing drug siramesine and the dual tyrosine kinase inhibitor lapatinib induce a synergistic ferroptosis through reduced heme oxygenase⁃1 （HO⁃1） levels［J］. Oxid Med Cell Longev, 2019,2019:9561281. doi: 10.1155/2019/9561281.
［23］	Pelle E, Huang X, Zhang Q, et al. Increased endogenous DNA oxidation correlates to increased iron levels in melanocytes relative to keratinocytes［J］. J Cosmet Sci, 2014,65（5）:277⁃284.
［24］	Wu X, Jin S, Yang Y, et al. Altered expression of ferroptosis markers and iron metabolism reveals a potential role of ferroptosis in vitiligo［J］. Pigment Cell Melanoma Res, 2022,35（3）:328⁃341. doi: 10.1111/pcmr.13032.
［25］	Orlik C, Deibel D, Küblbeck J, et al. Keratinocytes costimulate naive human T cells via CD2: a potential target to prevent the development of proinflammatory Th1 cells in the skin［J］. Cell Mol Immunol, 2020,17（4）:380⁃394. doi: 10.1038/s41423⁃019⁃0261⁃x.
［26］	Shou Y, Yang L, Yang Y, et al. Inhibition of keratinocyte ferroptosis suppresses psoriatic inflammation［J］. Cell Death Dis, 2021,12（11）:1009. doi: 10.1038/s41419⁃021⁃04284⁃5.
［27］	Rashmi R, Yuti AM, Basavaraj KH. Enhanced ferritin/iron ratio in psoriasis［J］. Indian J Med Res, 2012,135（5）:662⁃665.
［28］	Shahidi⁃Dadras M, Namazi N, Younespour S. Comparative analysis of serum copper, iron, ceruloplasmin, and transferrin levels in mild and severe psoriasis vulgaris in iranian patients［J］. Indian Dermatol Online J, 2017,8（4）:250⁃253. doi: 10. 4103/idoj.IDOJ_230_16.
［29］	Ahmed B, Qadir MI, Ghafoor S. Malignant melanoma: skin cancer⁃diagnosis, prevention, and treatment［J］. Crit Rev Eukaryot Gene Expr, 2020,30（4）:291⁃297. doi: 10.1615/Crit RevEukaryotGeneExpr.2020028454.
［30］	Wang Z, Jin D, Ma D, et al. Ferroptosis suppressed the growth of melanoma that may be related to DNA damage［J］. Dermatol Ther, 2019,32（4）:e12921. doi: 10.1111/dth.12921.
［31］	Hartman ML. Non⁃apoptotic cell death signaling pathways in melanoma［J］. Int J Mol Sci, 2020,21（8）:2980. doi: 10.3390/ijms21082980.
［32］	Tsoi J, Robert L, Paraiso K, et al. Multi⁃stage differentiation defines melanoma subtypes with differential vulnerability to drug⁃induced iron⁃dependent oxidative stress［J］. Cancer Cell, 2018,33（5）:890⁃904. doi: 10.1016/j.ccell.2018.03.017.
［33］	Viswanathan VS, Ryan MJ, Dhruv HD, et al. Dependency of a therapy⁃resistant state of cancer cells on a lipid peroxidase pathway［J］. Nature, 2017,547（7664）:453⁃457. doi: 10.1038/nature23007.
［34］	Hangauer MJ, Viswanathan VS, Ryan MJ, et al. Drug⁃tolerant persister cancer cells are vulnerable to GPX4 inhibition［J］. Nature, 2017,551（7679）:247⁃250. doi: 10.1038/nature24297.
［35］	Luo M, Wu L, Zhang K, et al. miR⁃137 regulates ferroptosis by targeting glutamine transporter SLC1A5 in melanoma［J］. Cell Death Differ, 2018,25（8）:1457⁃1472. doi: 10.1038/s41418⁃017⁃0053⁃8.
［36］	Zhang K, Wu L, Zhang P, et al. miR⁃9 regulates ferroptosis by targeting glutamic⁃oxaloacetic transaminase GOT1 in melanoma［J］. Mol Carcinog, 2018,57（11）:1566⁃1576. doi: 10.1002/mc. 22878.
［37］	Ubellacker JM, Tasdogan A, Ramesh V, et al. Lymph protects metastasizing melanoma cells from ferroptosis［J］. Nature, 2020,585（7823）:113⁃118. doi: 10.1038/s41586⁃020⁃2623⁃z.
［38］	Chen Q, Wang J, Xiang M, et al. The potential role of ferroptosis in systemic lupus erythematosus［J］. Front Immunol, 2022,13:855622. doi: 10.3389/fimmu.2022.855622.
［39］	Li P, Jiang M, Li K, et al. Glutathione peroxidase 4⁃regulated neutrophil ferroptosis induces systemic autoimmunity［J］. Nat Immunol, 2021,22（9）:1107⁃1117. doi: 10.1038/s41590⁃021⁃00993⁃3.
［40］	Wen Q, Liu J, Kang R, et al. The release and activity of HMGB1 in ferroptosis［J］. Biochem Biophys Res Commun, 2019,510（2）:278⁃283. doi: 10.1016/j.bbrc.2019.01.090.
［41］	Vats K, Kruglov O, Mizes A, et al. Keratinocyte death by ferroptosis initiates skin inflammation after UVB exposure［J］. Redox Biol, 2021,47:102143. doi: 10.1016/j.redox.2021.102143.
［42］	Liu T, Son M, Diamond B. HMGB1 in systemic lupus erythematosus［J］. Front Immunol, 2020,11:1057. doi: 10.3389/fimmu.2020.01057.
［43］	Ni S, Yuan Y, Kuang Y, et al. Iron metabolism and immune regulation［J］. Front Immunol, 2022,13:816282. doi: 10.3389/fimmu.2022.816282.

[1]	Zhang Congcong, Chen Hao. Ferroptosis in melanoma [J]. Chinese Journal of Dermatology, 2025, 58(5): 481-484.
[2]	Sun Yuxin, Huo Siyi, Chen Jiayu, Xiong Heping, Zhu Mingfang. COVID-19-associated skin diseases: a cross-sectional survey in Changsha, China [J]. Chinese Journal of Dermatology, 2025, 58(5): 464-469.
[3]	Committee on Psoriasis, Chinese Society of Dermatology. Expert proposal on apremilast for the treatment of psoriasis （2025 edition） [J]. Chinese Journal of Dermatology, 2025, 58(5): 416-424.
[4]	Li Ziyu, Lu Yan. Paying attention to severe skin diseases after COVID-19 [J]. Chinese Journal of Dermatology, 2025, 58(4): 378-383.
[5]	Group on Pediatric Dermatology, China Dermatologist Association, Committee on Psoriasis, Chinese Society of Dermatology. Expert consensus on the diagnosis and treatment of pediatric pustular psoriasis in China （2025 version） [J]. Chinese Journal of Dermatology, 2025, 58(4): 297-306.
[6]	He Chunxia, Jin Hongzhong . Principles, current status, challenges and perspectives in the diagnosis and treatment of critical dermatological emergencies [J]. Chinese Journal of Dermatology, 2025, 58(4): 307-314.
[7]	Li Yuancheng, Han Renqiang, Miao Weigang, Luo Pengfei. Incidence trends and age distribution of cutaneous melanoma in Jiangsu province from 2010 to 2019 [J]. Chinese Journal of Dermatology, 2025, 58(3): 228-233.
[8]	Li Xiuzhen, Xu Xiulian. Effects of interleukin-23 inhibitors on psoriasis comorbidities [J]. Chinese Journal of Dermatology, 2025, 58(3): 268-272.
[9]	Lianghong Chen Yan SUN Jing-Yu WANG. Benvitimod for the treatment of dermatoses [J]. Chinese Journal of Dermatology, 2025, 58(3): 266-268.
[10]	Chinese Association of Rehabilitation Dermatology, Chinese Society of Dermatology, Photomedicine Therapeutic Equipment Group, Committee on Skin Disease and Cosmetic Dermatology, China Association of Medical Equipment. Clinical application of red, blue, and yellow light therapy in dermatology: an expert consensus statement （2025 edition） [J]. Chinese Journal of Dermatology, 2025, 58(3): 209-215.
[11]	Dermatology Professional Committee of Chinese Research Hospital Society, China Dermatologist Association. Guideline on phototherapy for vitiligo （2025 edition） [J]. Chinese Journal of Dermatology, 2025, 58(3): 197-208.
[12]	Xu Zhuohong, Hu Yu, Gu Heng. Role of mesenchymal stem cell-derived exosomes in skin diseases [J]. Chinese Journal of Dermatology, 2025, 0(3): 20220881-e20220881.
[13]	Dong Yi, Yan Xin, Munire·Tayier, Zhang Xingqi. Application of machine learning in dermatology [J]. Chinese Journal of Dermatology, 2025, 0(3): 20240290-e20240290.
[14]	Wei Yalu, Shen Zhengyu. Spatial transcriptomics and its application in dermatology [J]. Chinese Journal of Dermatology, 2025, 0(3): 20220429-e20220429.
[15]	Wang Wenqiu, Li Chengxin, Wang Rui. Biologics for the treatment of psoriasis relapse: current status [J]. Chinese Journal of Dermatology, 2025, 0(3): 20230301-e20230301.

Ferroptosis in common skin diseases

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［43］

Related Articles 15

Metrics

Comments

Recommended 10